Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | FAAH | O00519 | 1/20 | 0.44 |
| ▸ | PHGDH | O43175 | 1/20 | 0.44 |
| ▸ | MGLL | Q99685 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.39 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL34368 | 0.82 | MEN1 (0.46) | MEN1KMT2AHTTFAAHPHGDH | |
| SCHEMBL14046945 | 0.78 | FAAH (0.46) | MEN1KMT2AHTTFAAHPHGDH | |
| SCHEMBL18715283 | 0.78 | MEN1 (0.42) | MEN1KMT2AHTTFAAHPHGDH | |
| Methylsulfanylmethane SCHEMBL27495758 | 0.77 | ALDH1A1 (0.56) | MEN1KMT2AHTTFAAHPHGDH | |
| SCHEMBL27490884 | 0.77 | NPSR1 (0.42) | MEN1KMT2AHTTFAAHPHGDH | |
| SCHEMBL9180532 | 0.77 | NPSR1 (0.42) | MEN1KMT2AHTTFAAHPHGDH | |
| SCHEMBL19148797 | 0.76 | KMT2A (0.41) | MEN1KMT2AHTTFAAHPHGDH | |
| SCHEMBL21087657 | 0.76 | KMT2A (0.41) | MEN1KMT2AHTTFAAHPHGDH | |
| SCHEMBL23178614 | 0.74 | ALDH1A1 (0.57) | ALDH1A1TSHRCA12CA1CA2 | |
| SCHEMBL20842915 | 0.74 | MEN1 (0.39) | MEN1KMT2AHTTFAAHPHGDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230359119-A1 | RESIST COMPOSITION AND PATTERN FORMING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-11-09 | — | — | US | disclosed |
| US-20230265094-A1 | RIPK1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2023-08-24 | — | — | US | disclosed |
| WO-2023116527-A1 | COMPOUND AS FAK INHIBITOR AND USE THEREOF | 微境生物医药科技(上海)有限公司 | 2023-06-29 | — | — | WO | disclosed |
| US-11124520-B2 | Cyclopenta[d]pyrimidines and substituted cyclopenta[d]pyrimidines as antitubulin and microtubule targeting agents, monocyclic pyrimidines as tubulin inhibitors, and pyrrolopyrimidines as targeted antifolates and tubulin and multiple receptor tyrosine kinase inhibitor and antitumor agents | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2021-09-21 | — | — | US | disclosed |
| US-20200290976-A1 | RADIOLABELED MICROTUBULE IMAGING COMPOUNDS AND USES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2020-09-17 | — | — | US | disclosed |
| US-20200181152-A1 | Cyclopenta[d]pyrimidines And Substituted Cyclopenta[d]pyrimidines As Antitubulin and Microtubule Targeting Agents, Monocyclic Pyrimidines As Tubulin Inhibitors, And Pyrrolopyrimidines As Targeted Antifolates And Tubulin and Multiple Receptor Tyrosine Kinase Inhibition And Antitumor Agents | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT | 2020-06-11 | — | — | US | disclosed |
| US-10538527-B2 | Cyclopenta[d]pyrimidines and substituted cyclopenta[d]pyrimidines as antitubulin and microtubule targeting agents, monocyclic pyrimidines as tubulin inhibitors, and pyrrolopyrimidines as targeted antifolates and tubulin and multiple receptor tyrosine kinase inhibition and antitumor agents | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2020-01-21 | — | — | US | disclosed |
| WO-2019170919-A1 | HYBRID MU OPIOID RECEPTOR AND NEUROPEPTIDE FF RECEPTOR BINDING MOLECULES, THEIR METHODS OF PREPARATION AND APPLICATIONS IN THERAPEUTIC TREATMENT | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2019-09-12 | — | — | WO | disclosed |
| US-20190241571-A1 | Cyclopenta[d]pyrimidines And Substituted Cyclopenta[d]pyrimidines As Antitubulin and Microtubule Targeting Agents, Monocyclic Pyrimidines As Tubulin Inhibitors, And Pyrrolopyrimidines As Targeted Antifolates And Tubulin and Multiple Receptor Tyrosine Kinase Inhibition And Antitumor Agents | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT | 2019-08-08 | — | — | US | disclosed |
| US-10239880-B2 | Cyclopenta[d]pyrimidines and substituted cyclopenta[d]pyrimidines as antitubulin and microtubule targeting agents, monocyclic pyrimidines as tubulin inhibitors, and pyrrolopyrimidines as targeted antifolates and tubulin and multiple receptor tyrosine kinase inhibition and antitumor agents | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2019-03-26 | — | — | US | disclosed |
| WO-2016168637-A2 | CYCLOPENTA[D]PYRIMIDINES AND SUBSTITUTED CYCLOPENTA[D]PYRIMIDINES AS ANTITUBULIN AND MICROTUBULE TARGETING AGENTS, MONOCYCLIC PYRIMIDINES AS TUBULIN INHIBITORS, AND PYRROLOPYRIMIDINES AS TARGETED ANTIFOLATES AND TUBULIN AND MULTIPLE RECEPTOR TYROSINE KINASE INHIBITION AND ANTITUMOR AGENTS | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2016-10-20 | — | — | WO | disclosed |
| US-20160304525-A1 | Cyclopenta[d]pyrimidines And Substituted Cyclopenta[d]pyrimidines As Antitubulin and Microtubule Targeting Agents, Monocyclic Pyrimidines As Tubulin Inhibitors, And Pyrrolopyrimidines As Targeted Antifolates And Tubulin and Multiple Receptor Tyrosine Kinase Inhibition And Antitumor Agents | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT | 2016-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160304525-A1 | Cyclopenta[d]pyrimidines And Substituted Cyclopenta[d]pyrimidines As Antitubulin and Microtubule Targeting Agents, Monocyclic Pyrimidines As Tubulin Inhibitors, And Pyrrolopyrimidines As Targeted Antifolates And Tubulin and Multiple Receptor Tyrosine Kinase Inhibition And Antitumor Agents | FOLR1, TUBB1, TUBA1C | MEN1 4498/4885KMT2A 2873/4885HTT 2724/4885 |
| US-20200181152-A1 | Cyclopenta[d]pyrimidines And Substituted Cyclopenta[d]pyrimidines As Antitubulin and Microtubule Targeting Agents, Monocyclic Pyrimidines As Tubulin Inhibitors, And Pyrrolopyrimidines As Targeted Antifolates And Tubulin and Multiple Receptor Tyrosine Kinase Inhibition And Antitumor Agents | FOLR1, DHFR, TUBB3 | MEN1 4455/4885KMT2A 3545/4885HTT 2846/4885 |
| US-20190241571-A1 | Cyclopenta[d]pyrimidines And Substituted Cyclopenta[d]pyrimidines As Antitubulin and Microtubule Targeting Agents, Monocyclic Pyrimidines As Tubulin Inhibitors, And Pyrrolopyrimidines As Targeted Antifolates And Tubulin and Multiple Receptor Tyrosine Kinase Inhibition And Antitumor Agents | TUBB, TUBB1, TUBA1C | MEN1 4615/4885KMT2A 2576/4885HTT 2487/4885 |
| US-10239880-B2 | Cyclopenta[d]pyrimidines and substituted cyclopenta[d]pyrimidines as antitubulin and microtubule targeting agents, monocyclic pyrimidines as tubulin inhibitors, and pyrrolopyrimidines as targeted antifolates and tubulin and multiple receptor tyrosine kinase inhibition and antitumor agents | FOLR1, TUBB1, TUBA1C | MEN1 4498/4885KMT2A 2873/4885HTT 2724/4885 |
| US-20230265094-A1 | RIPK1 INHIBITORS AND METHODS OF USE | RIPK1, RIPK2, RIPK3 | MEN1 2304/4885KMT2A 3938/4885HTT 3562/4885 |
| US-20200290976-A1 | RADIOLABELED MICROTUBULE IMAGING COMPOUNDS AND USES THEREOF | TUBB3, MAP2, MAPT | MEN1 758/4885KMT2A 3075/4885HTT 107/4885 |
| US-11124520-B2 | Cyclopenta[d]pyrimidines and substituted cyclopenta[d]pyrimidines as antitubulin and microtubule targeting agents, monocyclic pyrimidines as tubulin inhibitors, and pyrrolopyrimidines as targeted antifolates and tubulin and multiple receptor tyrosine kinase inhibitor and antitumor agents | FOLR1, DHFR, TUBB3 | MEN1 4430/4885KMT2A 3464/4885HTT 2839/4885 |
| US-10538527-B2 | Cyclopenta[d]pyrimidines and substituted cyclopenta[d]pyrimidines as antitubulin and microtubule targeting agents, monocyclic pyrimidines as tubulin inhibitors, and pyrrolopyrimidines as targeted antifolates and tubulin and multiple receptor tyrosine kinase inhibition and antitumor agents | TUBB, TUBB1, TUBA1C | MEN1 4615/4885KMT2A 2576/4885HTT 2487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.